Genetic Technologies’ COVID-19 Risk Test Now Available in US through Partnership with Infinity BiologiX
June 01 2021 - 8:00AM
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”,
“GTG”), a diversified Genomics and AI-driven preventative health
business, is pleased to announce the official launch of its
COVID-19 Serious Disease Risk Test (‘COVID-19 Risk Test’) in the US
through its partnership with Infinity BiologiX LLC (‘IBX’). IBX
will produce, distribute, and sell GENE’s test across its
established network,
https://ibx.bio/services/covid-19-severity-test/
Designed to predict disease severity using genetic and clinical
information the test provides a risk score to help individuals aged
18 years and over to understand their personal risk of contracting
a serious case of COVID-19. In addition, employers, governments,
and other public health entities may use the data to make informed
decisions about disease risk, treatment options, and vaccination
priorities. This will assist in guiding proactive steps to minimize
disease exposure and manage the pandemic in the weeks and months
ahead.
“This is a fantastic milestone for our team,” commented Simon
Morriss, CEO of Genetic Technologies. “Our COVID-19 Risk Test is a
crucial product that will provide individuals with the ability to
understand their personal risk associated with contracting a
serious case of this disease. Alongside existing treatment options
and vaccines, we believe this test will enable more insightful
decisions for states, workplaces and individuals on pathways
forward in managing this pandemic.”
IBX is a market-disrupting central laboratory supporting
academia, government, and industry. IBX provides global sample
collection, processing, storage, and analytical services integrated
with scientific and technical support in both the research and
clinical arenas. As a leader in biomaterials, IBX provides support
to the development of diagnostics, therapeutics, and research in
the genomics, precision, and regenerative medicine arenas.
Extensive experience with large-scale COVID testing and sample
processing made IBX a clear choice for this endeavor. Through its
labs in New Jersey and Minnesota and with partner organizations
around the US, the company is able to process over 100,000 risk
tests per day.
IBX launched its COVID-19 saliva-test in May 2020, after
receiving FDA Emergency Use Authorization. It was the first test to
utilize saliva as the primary biomaterial for SARS-CoV-2, and IBX
subsequently became the first company to offer an at-home
collection with this approach.
Developed by GENE, the COVID-19 risk test will be distributed
and sold in the US by IBX, released under GENE’s ‘powered by
GeneType’ brand, and is applicable to men and women ages 18 and up.
IBX will determine sales and end consumer pricing structure for the
risk test and will produce, distribute, and market it in the
US.
|
|
Investor Relations (AUS) Stephanie Ottens Market
Eye M: +61 434 405 400 E:
stephanie.ottens@marketeye.com.au |
Investor Relations and Media (US) Dave Gentry1 800
RED CHIP (733 2447) Cell: 407 491 4498 E:
dave@redchip.com |
About Genetic Technologies Limited Genetic
Technologies Limited (ASX: GTG; Nasdaq: GENE) is an Australian
based diversified molecular diagnostics company. GENE offers cancer
predictive testing and assessment tools to help physicians
proactively manage patient health. The company’s lead products,
GeneType for Breast Cancer for non-hereditary breast cancer and
GeneType for Colorectal Cancer, are clinically validated risk
assessment tests and are first in class. Genetic Technologies is
developing a pipeline of risk assessment products based on a world
leading technology platform created over the past 10 years.
For more information, please visit www.genetype.com
About Infinity BiologiX LLC: Infinity BiologiX
(IBX) is a market-disrupting central laboratory supporting
academia, government, and industry. IBX provides global sample
collection, processing, storage, and analytical services integrated
with scientific and technical support in both the research and
clinical arenas. As a leader in biomaterials, IBX provides support
to the development of diagnostics, therapeutics, and research in
the genomics, precision, and regenerative medicine arenas. IBX
previously operated as RUCDR Infinite Biologics before spinning off
from Rutgers University-New Brunswick in August 2020.
For more information, visit www.ibx.bio
Forward-Looking Statements
This press release may contain forward-looking statements about
the Company's expectations, beliefs or intentions regarding, among
other things, statements regarding the expected use of proceeds. In
addition, from time to time, the Company or its representatives
have made or may make forward-looking statements, orally or in
writing. Forward-looking statements can be identified by the use of
forward-looking words such as "believe," "expect," "intend,"
"plan," "may," "should" or "anticipate" or their negatives or other
variations of these words or other comparable words or by the fact
that these statements do not relate strictly to historical or
current matters. These forward-looking statements may be included
in, but are not limited to, various filings made by the Company
with the U.S. Securities and Exchange Commission, press releases or
oral statements made by or with the approval of one of the
Company's authorized executive officers. Forward-looking statements
relate to anticipated or expected events, activities, trends or
results as of the date they are made. Because forward-looking
statements relate to matters that have not yet occurred, these
statements are inherently subject to risks and uncertainties that
could cause the Company's actual results to differ materially from
any future results expressed or implied by the forward-looking
statements. Many factors could cause the Company's actual
activities or results to differ materially from the activities and
results anticipated in such forward-looking statements as detailed
in the Company's filings with the Securities and Exchange
Commission and in its periodic filings in Australia and the risks
and risk factors included therein. In addition, the Company
operates in an industry sector where securities values are highly
volatile and may be influenced by economic and other factors beyond
its control. The Company does not undertake any obligation to
publicly update these forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Sep 2023 to Sep 2024